TIA Scores' Mortality Predictions and Recurrent TIA and Stroke Prediction

July 17, 2024 updated by: Saglik Bilimleri Universitesi

The Role of TIA Scores and NIHSS Score in Predicting Early and Late Ischemic Stroke Risk in Patients Presenting With Transient Ischemic Attack to the Emergency Department

Our study adopts a prospective design. Our research aims to determine the significance of ABCD2, ABCD3-I, Canadian TIA Score, and NIHSS Score in predicting the likelihood of ischemic stroke within 30 days in patients presenting to the emergency department with transient ischemic attack (TIA)

Study Overview

Status

Recruiting

Conditions

Detailed Description

Our study is planned as follows: Patients diagnosed with transient ischemic attack (TIA) presenting to the emergency department will undergo scoring by researchers, although they will not intervene the treatment process of the patients. Patients will be contacted by researchers or their families to ascertain whether they experience a recurrent stroke or TIA within 30 days, and their current health status will be assessed. The collected information will be recorded.

The study will include patients diagnosed with transient ischemic attack (TIA) based on tests and imaging conducted at Ankara Etlik City Hospital's emergency department. The planned duration for data collection and analysis is one year.

Parameters to be examined:

Age Gender Physical examination findings Comorbidities (hypertension, coronary artery disease, valvular heart disease, COPD, asthma, diabetes, others) Neurological examination findings Time of symptom onset Admission status (intensive care unit / ward) Findings from ultrasound, computed tomography, and MRI imaging Length of hospital stay Mortality (yes/no)

We aim to collect data from approximately 300 patients within the course of one year for our study

Study Type

Observational

Enrollment (Estimated)

300

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Turkey
    • Yenimahalle
      • Ankara, Yenimahalle, Turkey, 06170
        • Recruiting
        • Etlik City Hospital
        • Contact:
        • Sub-Investigator:
          • tugba sanalp menekse, specialist
        • Sub-Investigator:
          • sefika ceren ture, resident
        • Principal Investigator:
          • gulsen akcay, ass. prof
        • Sub-Investigator:
          • bedriye muge sonmez, ass.prof.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

N/A

Sampling Method

Probability Sample

Study Population

patients over the age of 18 presenting to emergency department with symptoms of stroke and diagnosed with TIA will be enrolled to study and will be followed up for 30 days for recurrent TIA or stroke

Description

Inclusion Criteria:

Patients presenting to the emergency department and diagnosed with TIA Patients diagnosed with ischemic stroke who did not receive thrombolytic therapy based on NIHSS score Patients aged 18 and above Patients who consented by signing the informed consent form

Exclusion Criteria:

Patients diagnosed with hemorrhagic stroke Patients unwilling to participate in the study Patients with a history of trauma Patients unable to receive thrombolytic therapy for any reason (trauma, malignancy, etc.) Patients under the age of 18 Patients transferred from another hospital Patients who experienced cardiac arrest Patients who died for any reason other than ischemic stroke within 30 days Patients wishing to withdraw from the study at any time during the study period

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
TIA group
patients presenting with transient ischemic attack will be recorded and TIA scores and NIHSS score will be calculated, after 30 days follow-up, recurrent TIA and stroke rates will be determined

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
recurrent TIA or stroke
Time Frame: 30 days
recurrent TIA within 30 days of follow-up
30 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Saglik Bilimleri Universitesi

Collaborators

Ankara Etlik City Hospital

Investigators

  • Study Director: gulsen akcay, ass. prof., ass. prof. of organization

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 1, 2024

Primary Completion (Estimated)

June 1, 2025

Study Completion (Estimated)

June 1, 2025

Study Registration Dates

First Submitted

July 17, 2024

First Submitted That Met QC Criteria

July 17, 2024

First Posted (Actual)

July 23, 2024

Study Record Updates

Last Update Posted (Actual)

July 23, 2024

Last Update Submitted That Met QC Criteria

July 17, 2024

Last Verified

July 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • TIA Scores and Mortality

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Transient Ischemic Attack

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Australia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe